clavulanic acid has been researched along with clofazimine in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (20.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
Abalos, RM; dela Cruz, EC; Fajardo, TT; Veerasubramanian, P; Villahermosa, LG; Walsh, DS; Walsh, GP | 1 |
Caminero, JA; Scardigli, A | 1 |
Cavanaugh, JS; Cegielski, JP; Dalton, T; Ershova, J; Jou, R; Kurbatova, E; Wu, MH | 1 |
5 other study(ies) available for clavulanic acid and clofazimine
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Resolution of lepromatous leprosy after a short course of amoxicillin/clavulanic acid, followed by ofloxacin and clofazimine.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clavulanic Acid; Clofazimine; Drug Therapy, Combination; Female; Humans; Leprosy, Lepromatous; Mycobacterium leprae; Ofloxacin; Skin; Treatment Outcome | 1999 |
Classification of antituberculosis drugs: a new proposal based on the most recent evidence.
Topics: Antitubercular Agents; Carbapenems; Clavulanic Acid; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Humans; Infectious Disease Medicine; Linezolid; Nitroimidazoles; Oxazoles; Practice Guidelines as Topic; Tuberculosis, Multidrug-Resistant; World Health Organization | 2015 |
Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic/pharmacodynamic parameters.
Topics: Amoxicillin-Potassium Clavulanate Combination; Antitubercular Agents; beta-Lactamase Inhibitors; Clavulanic Acid; Clofazimine; Drug Discovery; Drug Resistance, Multiple, Bacterial; Humans; Leprostatic Agents; Meropenem; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Thienamycins; Tuberculosis, Multidrug-Resistant | 2017 |